Familial hemophagocytic lymphohistiocytosis and X-linked lymphoproliferative disease

Annals of the New York Academy of Sciences

Volumn 1238, Issue 1, 2011, Pages 106-121

  Marsh, Rebecca A ^a   Filipovich, Alexandra H ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Familial hemophagocytic lymphohistiocytosis; FHL; FHLH; Hemophagocytic lymphohistiocytosis; HLH; X linked lymphoproliferative disease; XLP

Indexed keywords

CYCLOSPORIN; DEXAMETHASONE; ETOPOSIDE; IMMUNOGLOBULIN; INDUCIBLE T CELL KINASE; INTERLEUKIN 2; PERFORIN; PHOSPHOTRANSFERASE; PRF1 PROTEIN; PROTEIN; PROTEIN SH2; RITUXIMAB; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN; STX11 PROTEIN; STXBP2 PROTEIN; SYNTAXIN; THYMOCYTE ANTIBODY; UNC13D PROTEIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; GENDER; GENE MUTATION; GENETIC DISORDER; GENETIC SUSCEPTIBILITY; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HUMAN; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; SURVIVAL; X CHROMOSOME LINKED DISORDER; X LINKED LYMPHOPROLIFERATIVE DISEASE;

EID: 82555192870     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06265.x     Document Type: Article

References (150)

1. Farquhar, J.W. & A.E. Claireaux. 1952. Familial haemophagocytic reticulosis. Arch. Dis. Child. 27: 519-525.
2. Bar, R.S., C.J. DeLor, K.P. Clausen, et al. 1974. Fatal infectious mononucleosis in a family. N. Engl. J. Med. 290: 363-367.
3. Ohadi, M., M.R. Lalloz, P. Sham, et al. 1999. Localization of a gene for familial hemophagocytic lymphohistiocytosis at chromosome 9q21.3-22 by homozygosity mapping. Am. J. Hum. Genet. 64: 165-171.
4. Stepp, S.E., R. Dufourcq-Lagelouse, F. Le Deist, et al. 1999. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 286: 1957-1959.
5. Feldmann, J., I. Callebaut, G. Raposo, et al. 2003. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 115: 461-473.
6. zur Stadt, U., S. Schmidt, B. Kasper, et al. 2005. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum. Mol. Genet. 14: 827-834.
7. Cote, M., M.M. Menager, A. Burgess, et al. 2009. Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells. J. Clin. Invest. 119: 3765-3773.
8. zur Stadt, U., J. Rohr, W. Seifert, et al. 2009. Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11. Am. J. Hum. Genet. 85: 482-492.
9. Henter, J.I., G. Elinder, O. Soder, et al. 1991. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood 78: 2918-2922.
10. Osugi, Y., J. Hara, S. Tagawa, et al. 1997. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood 89: 4100-4103.
11. Badovinac, V.P., S.E. Hamilton & J.T. Harty. 2003. Viral infection results in massive CD8+ T cell expansion and mortality in vaccinated perforin-deficient mice. Immunity 18: 463-474.
12. Jordan, M.B., D. Hildeman, J. Kappler & P. Marrack. 2004. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 104: 735-743.
13. Horne, A., C. Zheng, I. Lorenz, et al. 2005. Subtyping of natural killer cell cytotoxicity deficiencies in haemophagocytic lymphohistocytosis provides therapeutic guidance. Br. J. Haematol. 129: 658-666.
14. Voskoboinik, I., M.A. Dunstone, K. Baran, et al. 2010. Perforin: structure, function, and role in human immunopathology. Immunol. Rev. 235: 35-54.
15. Law, R.H., N. Lukoyanova, I. Voskoboinik, et al. 2010. The structural basis for membrane binding and pore formation by lymphocyte perforin. Nature 468: 447-451.
16. Zur Stadt, U., K. Beutel, S. Kolberg, et al. 2006. Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A. Hum. Mutat. 27: 62-68.
17. Goransdotter Ericson, K., B. Fadeel, S. Nilsson-Ardnor, et al. 2001. Spectrum of perforin gene mutations in familial hemophagocytic lymphohistiocytosis. Am. J. Hum. Genet. 68: 590-597.
18. Molleran Lee, S., J. Villanueva, J. Sumegi, et al. 2004. Characterisation of diverse PRF1 mutations leading to decreased natural killer cell activity in North American families with haemophagocytic lymphohistiocytosis. J. Med. Genet. 41: 137-144.
19. Nagai, K., K. Yamamoto, H. Fujiwara, et al. 2010. Subtypes of familial hemophagocytic lymphohistiocytosis in Japan based on genetic and functional analyses of cytotoxic T lymphocytes. PLoS One 5: e14173.
20. Trizzino, A., U. zur Stadt, I. Ueda, et al. 2008. Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis due to perforin mutations. J. Med. Genet. 45: 15-21.
21. Lee, S.M., J. Sumegi, J. Villanueva, et al. 2006. Patients of African ancestry with hemophagocytic lymphohistiocytosis share a common haplotype of PRF1 with a 50delT mutation. J. Pediatr. 149: 134-137.
22. Ueda, I., A. Morimoto, T. Inaba, et al. 2003. Characteristic perforin gene mutations of haemophagocytic lymphohistiocytosis patients in Japan. Br. J. Haematol. 121: 503-510.
23. Horne, A., K.G. Ramme, E. Rudd, et al. 2008. Characterization of PRF1, STX11 and UNC13D genotype-phenotype correlations in familial hemophagocytic lymphohistiocytosis. Br. J. Haematol. 143: 75-83.
24. Ishii, E., I. Ueda, R. Shirakawa, et al. 2005. Genetic subtypes of familial hemophagocytic lymphohistiocytosis: correlations with clinical features and cytotoxic T lymphocyte/natural killer cell functions. Blood 105: 3442-3448.
25. Ueda, I., E. Ishii, A. Morimoto, et al. 2006. Correlation between phenotypic heterogeneity and gene mutational characteristics in familial hemophagocytic lymphohistiocytosis (FHL). Pediatr. Blood Cancer 46: 482-488.
26. Risma, K.A., R.W. Frayer, A.H. Filipovich & J. Sumegi. 2006. Aberrant maturation of mutant perforin underlies the clinical diversity of hemophagocytic lymphohistiocytosis. J. Clin. Invest. 116: 182-192.
27. Zhang, K., M.B. Jordan, R.A. Marsh, et al. 2011. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial hemophagocytic lymphohistiocytosis. Blood. [Epub ahead of print.] PMID21881043.
28. Yoon, H.S., H.J. Kim, K.H. Yoo, et al. 2010. UNC13D is the predominant causative gene with recurrent splicing mutations in Korean patients with familial hemophagocytic lymphohistiocytosis. Haematologica 95: 622-626.
29. Bryceson, Y.T., E. Rudd, C. Zheng, et al. 2007. Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients. Blood 110: 1906-1915.
30. Arneson, L.N., A. Brickshawana, C.M. Segovis, et al. 2007. Cutting edge: syntaxin 11 regulates lymphocyte-mediated secretion and cytotoxicity. J. Immunol. 179: 3397-3401.
31. Marsh, R.A., N. Satake, J. Biroschak, et al. 2010. STX11 mutations and clinical phenotypes of familial hemophagocytic lymphohistiocytosis in North America. Pediatr. Blood Cancer 55: 134-140.
32. Macartney, C.A., S. Weitzman, S.M. Wood, et al. 2011. Unusual functional manifestations of a novel STX11 frameshift mutation in two infants with familial hemophagocytic lymphohistiocytosis type 4 (FHL4). Pediatr. Blood Cancer 56: 654-657.
33. Danielian, S., N. Basile, C. Rocco, et al. 2010. Novel syntaxin 11 gene (STX11) mutation in three Argentinean patients with hemophagocytic lymphohistiocytosis. J. Clin. Immunol. 30: 330-337.
34. Johnson, J., K. Zhang, K. Huizenga, et al. 2010. STXBP2 (MUNC18-2) mutations in North American patients with familial hemophagocytic lymphohistiocytosis. In Proceedings of theASPHO 23rd Annual Meeting 2010 [Abstract], Montreal, Quebec, Canada.
35. Barbosa, M.D., Q.A. Nguyen, V.T. Tchernev, et al. 1996. Identification of the homologous beige and Chediak-Higashi syndrome genes. Nature 382: 262-265.
36. Nagle, D.L., M.A. Karim, E.A. Woolf, et al. 1996. Identification and mutation analysis of the complete gene for Chediak-Higashi syndrome. Nat. Genet. 14: 307-311.
37. Dell'Angelica, E.C., V. Shotelersuk, R.C. Aguilar, et al. 1999. Altered trafficking of lysosomal proteins in Hermansky-Pudlak syndrome due to mutations in the beta 3A subunit of the AP-3 adaptor. Mol. Cell. 3: 11-21.
38. Enders, A., B. Zieger, K. Schwarz, et al. 2006. Lethal hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type II. Blood 108: 81-87.
39. Menasche, G., E. Pastural, J. Feldmann, et al. 2000. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat. Genet. 25: 173-176.
40. Meeths, M., Y.T. Bryceson, E. Rudd, et al. 2010. Clinical presentation of Griscelli syndrome type 2 and spectrum of RAB27A mutations. Pediatr. Blood Cancer 54: 563-572.
41. Marsh, R.A., L. Madden, B.J. Kitchen, et al. 2010. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood 116: 1079-1082.
42. Rigaud, S., M.C. Fondaneche, N. Lambert, et al. 2006. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 444: 110-114.
43. Huck, K., O. Feyen, T. Niehues, et al. 2009. Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J. Clin. Invest. 119: 1350-1358.
44. Coffey, A.J., R.A. Brooksbank, O. Brandau, et al. 1998. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat. Genet. 20: 129-135.
45. Sayos, J., C. Wu, M. Morra, et al. 1998. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 395: 462-469.
46. Nichols, K.E., D.P. Harkin, S. Levitz, et al. 1998. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc. Natl. Acad. Sci. USA 95: 13765-13770.
47. Ma, C.S., K.E. Nichols & S.G. Tangye. 2007. Regulation of cellular and humoral immune responses by the SLAM and SAP families of molecules. Annu. Rev. Immunol. 25: 337-379.
48. Schwartzberg, P.L., K.L. Mueller, H. Qi & J.L. Cannons. 2009. SLAM receptors and SAP influence lymphocyte interactions, development and function. Nat. Rev. Immunol. 9: 39-46.
49. Latour, S. & A. Veillette. 2003. Molecular and immunological basis of X-linked lymphoproliferative disease. Immunol. Rev. 192: 212-224.
50. Cannons, J.L., S.G. Tangye & P.L. Schwartzberg. 2011. SLAM family receptors and SAP adaptors in immunity. Annu. Rev. Immunol. 29: 665-705.
51. Rezaei, N., E. Mahmoudi, A. Aghamohammadi, et al. 2011. X-linked lymphoproliferative syndrome: a genetic condition typified by the triad of infection, immunodeficiency and lymphoma. Br. J. Haematol. 152: 13-30.
52. Latour, S. & A. Veillette. 2004. The SAP family of adaptors in immune regulation. Semin. Immunol. 16: 409-419.
53. Lewis, J., L.J. Eiben, D.L. Nelson, et al. 2001. Distinct interactions of the X-linked lymphoproliferative syndrome gene product SAP with cytoplasmic domains of members of the CD2 receptor family. Clin. Immunol. 100: 15-23.
54. Chan, B., A. Lanyi, H.K. Song, et al. 2003. SAP couples Fyn to SLAM immune receptors. Nat. Cell Biol. 5: 155-160.
55. Latour, S., R. Roncagalli, R. Chen, et al. 2003. Binding of SAP SH2 domain to FynT SH3 domain reveals a novel mechanism of receptor signalling in immune regulation. Nat. Cell Biol. 5: 149-154.
56. Simarro, M., A. Lanyi, D. Howie, et al. 2004. SAP increases FynT kinase activity and is required for phosphorylation of SLAM and Ly9. Int. Immunol. 16: 727-736.
57. Li, C., D. Schibli & S.S. Li. 2009. The XLP syndrome protein SAP interacts with SH3 proteins to regulate T cell signaling and proliferation. Cell. Signal. 21: 111-119.
58. Gu, C., S.G. Tangye, X. Sun, et al. 2006. The X-linked lymphoproliferative disease gene product SAP associates with PAK-interacting exchange factor and participates in T cell activation. Proc. Natl. Acad. Sci. USA 103: 14447-14452.
59. Sylla, B.S., K. Murphy, E. Cahir-McFarland, et al. 2000. The X-linked lymphoproliferative syndrome gene product SH2D1A associates with p62dok (Dok1) and activates NF-kappa B. Proc. Natl. Acad. Sci. USA 97: 7470-7475.
60. Parolini, S., C. Bottino, M. Falco, et al. 2000. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J. Exp. Med. 192: 337-346.
61. Dupre, L., G. Andolfi, S.G. Tangye, et al. 2005. SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells. Blood 105: 4383-4389.
62. Eissmann, P., L. Beauchamp, J. Wooters, et al. 2005. Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244). Blood 105: 4722-4729.
63. Tangye, S.G., J.H. Phillips, L.L. Lanier & K.E. Nichols. 2000. Functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome. J. Immunol. 165: 2932-2936.
64. Sharifi, R., J.C. Sinclair, K.C. Gilmour, et al. 2004. SAP mediates specific cytotoxic T-cell functions in X-linked lymphoproliferative disease. Blood 103: 3821-3827.
65. Hislop, A.D., U. Palendira, A.M. Leese, et al. 2010. Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets. Blood 116: 3249-3257.
66. Nakajima, H., M. Cella, A. Bouchon, et al. 2000. Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity. Eur. J. Immunol. 30: 3309-3318.
67. Bloch-Queyrat, C., M.C. Fondaneche, R. Chen, et al. 2005. Regulation of natural cytotoxicity by the adaptor SAP and the Src-related kinase Fyn. J. Exp. Med. 202: 181-192.
68. Nagy, N., L. Matskova, L.L. Kis, et al. 2009. The proapoptotic function of SAP provides a clue to the clinical picture of X-linked lymphoproliferative disease. Proc. Natl. Acad. Sci. USA 106: 11966-11971.
69. Nagy, N. & E. Klein. 2010. Deficiency of the proapoptotic SAP function in X-linked lymphoproliferative disease aggravates Epstein-Barr virus (EBV) induced mononucleosis and promotes lymphoma development. Immunol. Lett. 130: 13-18.
70. Snow, A.L., R.A. Marsh, S.M. Krummey, et al. 2009. Restimulation-induced apoptosis of T cells is impaired in patients with X-linked lymphoproliferative disease caused by SAP deficiency. J. Clin. Invest. 119: 2976-2989.
71. Ma, C.S., N.J. Hare, K.E. Nichols, et al. 2005. Impaired humoral immunity in X-linked lymphoproliferative disease is associated with defective IL-10 production by CD4+ T cells. J. Clin. Invest. 115: 1049-1059.
72. Cannons, J.L., L.J. Yu, D. Jankovic, et al. 2006. SAP regulates T cell-mediated help for humoral immunity by a mechanism distinct from cytokine regulation. J. Exp. Med. 203: 1551-1565.
73. Qi, H., J.L. Cannons, F. Klauschen, et al. 2008. SAP-controlled T-B cell interactions underlie germinal centre formation. Nature 455: 764-769.
74. Cannons, J.L., H. Qi, K.T. Lu, et al. 2010. Optimal germinal center responses require a multistage T cell:B cell adhesion process involving integrins, SLAM-associated protein, and CD84. Immunity 32: 253-265.
75. Ma, C.S. & E.K. Deenick. 2011. The role of SAP and SLAM family molecules in the humoral immune response. Ann. N. Y. Acad. Sci. 1217: 32-44.
76. Nichols, K.E., J. Hom, S.Y. Gong, et al. 2005. Regulation of NKT cell development by SAP, the protein defective in XLP. Nat. Med. 11: 340-345.
77. Pasquier, B., L. Yin, M.C. Fondaneche, et al. 2005. Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product. J. Exp. Med. 201: 695-701.
78. Chung, B., A. Aoukaty, J. Dutz, et al. 2005. Signaling lymphocytic activation molecule-associated protein controls NKT cell functions. J. Immunol. 174: 3153-3157.
79. Uren, A.G., M. Pakusch, C.J. Hawkins, et al. 1996. Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors. Proc. Natl. Acad. Sci. USA 93: 4974-4978.
80. Liston, P., N. Roy, K. Tamai, et al. 1996. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature 379: 349-353.
81. Duckett, C.S., V.E. Nava, R.W. Gedrich, et al. 1996. A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. EMBO J. 15: 2685-2694.
82. Hinds, M.G., R.S. Norton, D.L. Vaux & C.L. Day. 1999. Solution structure of a baculoviral inhibitor of apoptosis (IAP) repeat. Nat. Struct. Biol. 6: 648-651.
83. Scott, F.L., J.B. Denault, S.J. Riedl, et al. 2005. XIAP inhibits caspase-3 and -7 using two binding sites: evolutionarily conserved mechanism of IAPs. EMBO J. 24: 645-655.
84. Chai, J., E. Shiozaki, S.M. Srinivasula, et al. 2001. Structural basis of caspase-7 inhibition by XIAP. Cell 104: 769-780.
85. Shiozaki, E.N., J. Chai, D.J. Rigotti, et al. 2003. Mechanism of XIAP-mediated inhibition of caspase-9. Mol. Cell 11: 519-527.
86. Huang, Y., Y.C. Park, R.L. Rich, et al. 2001. Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell 104: 781-790.
87. Rumble, J.M., K.A. Oetjen, P.L. Stein, et al. 2009. Phenotypic differences between mice deficient in XIAP and SAP, two factors targeted in X-linked lymphoproliferative syndrome (XLP). Cell. Immunol. 259: 82-89.
88. Marsh, R.A., J. Villanueva, M.O. Kim, et al. 2009. Patients with X-linked lymphoproliferative disease due to BIRC4 mutation have normal invariant natural killer T-cell populations. Clin. Immunol. 132: 116-123.
89. Damgaard, R.B. & M. Gyrd-Hansen. 2011. Inhibitor of apoptosis (IAP) proteins in regulation of inflammation and innate immunity. Discov. Med. 11: 221-231.
90. Krieg, A., R.G. Correa, J.B. Garrison, et al. 2009. XIAP mediates NOD signaling via interaction with RIP2. Proc. Natl. Acad. Sci. USA 106: 14524-14529.
91. Lu, M., S.C. Lin, Y. Huang, et al. 2007. XIAP induces NF-kappaB activation via the BIR1/TAB1 interaction and BIR1 dimerization. Mol. Cell 26: 689-702.
92. Yamaguchi, K., S. Nagai, J. Ninomiya-Tsuji, et al. 1999. XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway. EMBO J. 18: 179-187.
93. Sanna, M.G., C.S. Duckett, B.W. Richter, et al. 1998. Selective activation of JNK1 is necessary for the anti-apoptotic activity of hILP. Proc. Natl. Acad. Sci. USA 95: 6015-6020.
94. Kaur, S., F. Wang, M. Venkatraman & M. Arsura. 2005. X-linked inhibitor of apoptosis (XIAP) inhibits c-Jun N-terminal kinase 1 (JNK1) activation by transforming growth factor beta1 (TGF-beta1) through ubiquitin-mediated proteosomal degradation of the TGF-beta1-activated kinase 1 (TAK1). J. Biol. Chem. 280: 38599-38608.
95. Bauler, L.D., C.S. Duckett & M.X. O'Riordan. 2008. XIAP regulates cytosol-specific innate immunity to Listeria infection. PLoS Pathog. 4: e1000142.
96. Prakash, H., M. Albrecht, D. Becker, et al. 2010. Deficiency of XIAP leads to sensitization for Chlamydophila pneumoniae pulmonary infection and dysregulation of innate immune response in mice. J. Biol. Chem. 285: 20291-20302.
97. Burstein, E., L. Ganesh, R.D. Dick, et al. 2004. A novel role for XIAP in copper homeostasis through regulation of MURR1. EMBO J. 23: 244-254.
98. Wilkinson, J.C., A.S. Wilkinson, S. Galban, et al. 2008. Apoptosis-inducing factor is a target for ubiquitination through interaction with XIAP. Mol. Cell. Biol. 28: 237-247.
99. Stepensky, P., M. Weintraub, A. Yanir, et al. 2011. IL-2-inducible T-cell kinase deficiency: clinical presentation and therapeutic approach. Haematologica 96: 472-476.
100. Readinger, J.A., K.L. Mueller, A.M. Venegas, et al. 2009. Tec kinases regulate T-lymphocyte development and function: new insights into the roles of Itk and Rlk/Txk. Immunol. Rev. 228: 93-114.
101. Prince, A.L., C.C. Yin, M.E. Enos, et al. 2009. The Tec kinases Itk and Rlk regulate conventional versus innate T-cell development. Immunol. Rev. 228: 115-131.
102. Gadue, P. & P.L. Stein. 2002. NK T cell precursors exhibit differential cytokine regulation and require Itk for efficient maturation. J. Immunol. 169: 2397-2406.
103. Felices, M. & L.J. Berg. 2008. The Tec kinases Itk and Rlk regulate NKT cell maturation, cytokine production, and survival. J. Immunol. 180: 3007-3018.
104. Miller, A.T. & L.J. Berg. 2002. Defective Fas ligand expression and activation-induced cell death in the absence of IL-2-inducible T cell kinase. J. Immunol. 168: 2163-2172.
105. Atherly, L.O., M.A. Brehm, R.M. Welsh & L.J. Berg. 2006. Tec kinases Itk and Rlk are required for CD8+ T cell responses to virus infection independent of their role in CD4+T cell help. J. Immunol. 176: 1571-1581.
106. Linka, R.M., K. Huck, F. Krux, et al. 2010. Germline mutations within the IL2-inducible T cell kinase impede T cell differentiation or survival, cause protein destabilisation, loss of membrane recruitment and lead to severe EBV lymphoproliferation. Am. Soc. Hematol. [Abstract], Orlando, Florida.
107. Khurana, D., L.N. Arneson, R.A. Schoon, et al. 2007. Differential regulation of human NK cell-mediated cytotoxicity by the tyrosine kinase Itk. J. Immunol. 178: 3575-3582.
108. Henter, J.I., A. Horne, M. Arico, et al. 2007. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 48: 124-131.
109. Horne, A., H. Trottestam, M. Arico, et al. 2008. Frequency and spectrum of central nervous system involvement in 193 children with haemophagocytic lymphohistiocytosis. Br. J. Haematol. 140: 327-335.
110. Maakaroun, N.R., A. Moanna, J.T. Jacob & H. Albrecht. 2010. Viral infections associated with haemophagocytic syndrome. Rev. Med. Virol. 20: 93-105.
111. Purtilo, D.T., C.K. Cassel, J.P. Yang & R. Harper. 1975. X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet 1: 935-940.
112. Seemayer, T.A., T.G. Gross, R.M. Egeler, et al. 1995. X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr. Res. 38: 471-478.
113. Booth, C., K.C. Gilmour, P. Veys, et al. 2011. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood 117: 53-62.
114. Pachlopnik Schmid, J., D. Canioni, D. Moshous, et al. 2011. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood 117: 1522-1529.
115. Eastwood, D., K.C. Gilmour, K. Nistala, et al. 2004. Prevalence of SAP gene defects in male patients diagnosed with common variable immunodeficiency. Clin. Exp. Immunol. 137: 584-588.
116. Zhao, M., H. Kanegane, K. Ouchi, et al. 2010. A novel XIAP mutation in a Japanese boy with recurrent pancytopenia and splenomegaly. Haematologica 95: 688-689.
117. Worthey, E.A., A.N. Mayer, G.D. Syverson, et al. 2011. Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet. Med. 13: 255-262.
118. Rezaei, N., M. Hedayat, A. Aghamohammadi & K.E. Nichols. 2011. Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies. J. Allergy Clin. Immunol. 127: 1329-1341, e1322; quiz 1342-1323.
119. Kogawa, K., S.M. Lee, J. Villanueva, et al. 2002. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood 99: 61-66.
120. Shinozaki, K., H. Kanegane, H. Matsukura, et al. 2002. Activation-dependent T cell expression of the X-linked lymphoproliferative disease gene product SLAM-associated protein and its assessment for patient detection. Int. Immunol. 14: 1215-1223.
121. Tabata, Y., J. Villanueva, S.M. Lee, et al. 2005. Rapid detection of intracellular SH2D1A protein in cytotoxic lymphocytes from patients with X-linked lymphoproliferative disease and their family members. Blood 105: 3066-3071.
122. Marsh, R.A., J. Villanueva, K. Zhang, et al. 2009. A rapid flow cytometric screening test for X-linked lymphoproliferative disease due to XIAP deficiency. Cytometry B Clin. Cytom. 76: 334-344.
123. Betts, M.R., J.M. Brenchley, D.A. Price, et al. 2003. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J. Immunol. Methods 281: 65-78.
124. Marcenaro, S., F. Gallo, S. Martini, et al. 2006. Analysis of natural killer-cell function in familial hemophagocytic lymphohistiocytosis (FHL): defective CD107a surface expression heralds Munc13-4 defect and discriminates between genetic subtypes of the disease. Blood 108: 2316-2323.
125. Gholam, C., S. Grigoriadou, K.C. Gilmour & H.B. Gaspar. 2011. Familial haemophagocytic lymphohistiocytosis: advances in the genetic basis, diagnosis and management. Clin. Exp. Immunol. 163: 271-283.
126. Marsh, R.A., J.J. Bleesing & A.H. Filipovich. 2010. Using flow cytometry to screen patients for X-linked lymphoproliferative disease due to SAP deficiency and XIAP deficiency. J. Immunol. Methods 362: 1-9.
127. Henter, J.I., A. Samuelsson-Horne, M. Arico, et al. 2002. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 100: 2367-2373.
128. Mahlaoui, N., M. Ouachee-Chardin, G. de Saint Basile, et al. 2007. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients. Pediatrics 120: e622-e628.
129. Bruck, N., M. Suttorp, M. Kabus, et al. 2011. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J. Clin. Rheumatol. 17: 23-27.
130. Henzan, T., K. Nagafuji, H. Tsukamoto, et al. 2006. Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis. Am. J. Hematol. 81: 59-61.
131. Imashuku, S., S. Hibi, T. Ohara, et al. 1999. Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society. Blood. 93: 1869-1874.
132. Olin, R.L., K.E. Nichols, M. Naghashpour, et al. 2008. Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis. Am. J. Hematol. 83: 747-749.
133. Strout, M.P., S. Seropian & N. Berliner. 2010. Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis. Nat. Rev. Clin. Oncol. 7: 415-420.
134. Tomaske, M., O. Amon, A. Bosk, et al. 2002. Alpha-CD25 antibody treatment in a child with hemophagocytic lymphohistiocytosis. Med. Pediatr. Oncol. 38: 141-142.
135. Milone, M.C., D.E. Tsai, R.L. Hodinka, et al. 2005. Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood 105: 994-996.
136. Balamuth, N.J., K.E. Nichols, M. Paessler & D.T. Teachey. 2007. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis. J. Pediatr. Hematol. Oncol. 29: 569-573.
137. Arico, M., G. Janka, A. Fischer, et al. 1996. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society. Leukemia 10: 197-203.
138. Horne, A., G. Janka, R. Maarten Egeler, et al. 2005. Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. Br. J. Haematol. 129: 622-630.
139. Ouachee-Chardin, M., C. Elie, G. de Saint Basile, et al. 2006. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients. Pediatrics 117: e743-e750.
140. Baker, K.S., A.H. Filipovich, T.G. Gross, et al. 2008. Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Bone Marrow Transplant. 42: 175-180.
141. Cesaro, S., F. Locatelli, E. Lanino, et al. 2008. Hematopoietic stem cell transplantation for hemophagocytic lymphohistiocytosis: a retrospective analysis of data from the Italian Association of Pediatric Hematology Oncology (AIEOP). Haematologica 93: 1694-1701.
142. Yoon, H.S., H.J. Im, H.N. Moon, et al. 2010. The outcome of hematopoietic stem cell transplantation in Korean children with hemophagocytic lymphohistiocytosis. Pediatr. Transplant. 14: 735-740.
143. Marsh, R.A., G. Vaughn, M.O. Kim, et al. 2010. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood 116: 5824-5831.
144. Ohga, S., K. Kudo, E. Ishii, et al. 2010. Hematopoietic stem cell transplantation for familial hemophagocytic lymphohistiocytosis and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan. Pediatr. Blood Cancer 54: 299-306.
145. Marsh, R.A., M.B. Jordan & A.H. Filipovich. 2011. Reduced-intensity conditioning haematopoietic cell transplantation for haemophagocytic lymphohistiocytosis: an important step forward. Br. J. Haematol. 154: 556-563.
146. Amrolia, P., H.B. Gaspar, A. Hassan, et al. 2000. Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. Blood 96: 1239-1246.
147. Slatter, M.A., A. Bhattacharya, M. Abinun, et al. 2005. Outcome of boost haemopoietic stem cell transplant for decreased donor chimerism or graft dysfunction in primary immunodeficiency. Bone Marrow Transplant. 35: 683-689.
148. Shenoy, S., W.J. Grossman, J. DiPersio, et al. 2005. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant. 35: 345-352.
149. Cooper, N., K. Rao, K. Gilmour, et al. 2006. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood 107: 1233-1236.
150. Cooper, N., K. Rao, N. Goulden, et al. 2008. The use of reduced-intensity stem cell transplantation in haemophagocytic lymphohistiocytosis and Langerhans cell histiocytosis. Bone Marrow Transplant. 42(Suppl 2): S47-S50.